Specify a stock or a cryptocurrency in the search bar to get a summary
Ayala Pharmaceuticals Inc.
ADXSAyala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware. Address: 1007 North Orange Street, Wilmington, DE, United States, 19802
Analytics
WallStreet Target Price
4 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ADXS
Dividend Analytics ADXS
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ADXS
Stock Valuation ADXS
Financials ADXS
Results | 2019 | Dynamics |